Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;35(2):e15228.
doi: 10.1111/dth.15228. Epub 2021 Nov 30.

Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study

Alessandra Narcisi  1 , Mario Valenti  1   2 , Andrea Cortese  1   2 , Francesco Toso  1   2 , Giulia Pavia  1   2 , Luigi Gargiulo  1   2 , Riccardo Borroni  1   2 , Antonio Costanzo  1   2
Affiliations

Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study

Alessandra Narcisi et al. Dermatol Ther. 2022 Feb.

Abstract

Scalp is a frequent localization of psoriasis that has a massive impact on patient's quality of life. Managing this psoriasis' manifestation is often challenging, thus biologic drugs are widely used as a treatment option in refractory scalp psoriasis. The aim of our study is to retrospectively compare the efficacy of anti-interleukin (IL) 23 drugs (guselkumab, tildrakizumab, risankizumab) and anti-IL17 or anti-IL17RA biologics (secukinumab, ixekizumab, and brodalumab) in real-life patients affected by scalp psoriasis. One hundred twenty-seven patients with a clinical diagnosis of scalp psoriasis and a baseline scalp Physician Global Assessment ≥3 were enrolled; 65 patients were treated with anti-IL23 and anti-IL62 with anti-IL17 or anti-IL17RA. Statistical analysis trough χ2 test was performed in order to evaluate the percentage of response among the two groups of patients. Responders' percentage of patients under anti-IL23 was 41.5%, 75.4%, 88.1%, 87.5%, 93.7%, and 100% at Week 4, 16, 48, 96, and 144, respectively. In the group on anti-IL17 was 62.9%, 90.3%, 91.2%, 97.3%, 96.9%, and 95.2% at Week 4, 16, 48, 96, and 144, respectively. Both anti-IL17 and anti-IL23 appeared to be effective on scalp psoriasis; in particular patients treated with anti-IL17 drugs reached a faster significant reduction of the lesions; on the other hand, anti-IL23 monoclonal antibodies were slightly superior in maintaining the clinical improvement through the follow-up.

Keywords: anti-IL17; anti-IL23; biologics; psoriasis; scalp.

PubMed Disclaimer

References

REFERENCES

    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960.
    1. Camela E, Ocampo-Garza SS, Cinelli E, Villani A, Fabbrocini G, Megna M. Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatol Ther. 2021;34:e14857.
    1. Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971.
    1. Megna M, Cirillo T, Balato A, Balato N, Gallo L. Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs. J Eur Acad Dermatol Venereol. 2019;33(1):e22-e23.
    1. Narcisi A, Valenti M, De Simone C, et al. Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients. J Dermatolog Treat. 2021;10:1-4.

Substances

LinkOut - more resources